83 reports of this reaction
3.1% of all ARGATROBAN reports
#5 most reported adverse reaction
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED is the #5 most commonly reported adverse reaction for ARGATROBAN, manufactured by Accord Healthcare Inc.. There are 83 FDA adverse event reports linking ARGATROBAN to ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED. This represents approximately 3.1% of all 2,692 adverse event reports for this drug.
Patients taking ARGATROBAN who experience activated partial thromboplastin time prolonged should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED is moderately reported among ARGATROBAN users, representing a notable but not dominant share of adverse events.
In addition to activated partial thromboplastin time prolonged, the following adverse reactions have been reported for ARGATROBAN:
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED has been reported as an adverse event in 83 FDA reports for ARGATROBAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED accounts for approximately 3.1% of all adverse event reports for ARGATROBAN, making it a notable side effect.
If you experience activated partial thromboplastin time prolonged while taking ARGATROBAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.